China News Service, December 28, According to Taiwan's "Central News Agency", Taiwan's "Disease Control Agency" announced on the 27th that a 0.25mL publicly paid influenza vaccine produced by the Sanofi pharmaceutical factory had black spots in it, and 12,000 doses of this batch of vaccines were suspended. In addition, after vaccination of the same batch, four adverse reaction cases were reported, including 3 mild symptoms, and one vaccinated person had symptoms of left and right cheek asymmetry, but it had improved.
abnormal vaccine. Photo provided by Taiwan's "Central News Agency"/Taiwan's "Disease Control Agency"
Taiwan's "Disease Control Agency" Zhuang Renxiang said on the evening of the 27th that the same batch number of abnormal vaccines discovered this time have a total of 157,000 doses, and they will be distributed to all counties and cities in Taiwan starting from October 8. At present, about 12,000 doses are left, and they have been notified to be suspended.
Zhuang Renxiang pointed out that there were 4 cases of adverse reactions reported in the same batch of vaccines, 3 of which were mild symptoms, such as rash, itching, fever, decreased appetite, cough, sneezing, etc. One case was the vaccinated person's symptoms of left and right cheeks the next day, but it has improved. However, vaccination and adverse reactions may not be causal. Although there have been similar reports of adverse reactions in the past, current scientific evidence cannot be determined to be caused by vaccines.
0.25mL0.25mL publicly paid influenza vaccine is for children under 3 years old. In 2018, vaccine defects occurred in Taiwan, which affected parents' confidence. It has been difficult to improve the use of injections. There are still more than 36,000 doses left.
Zhuang Renxiang said that the same batch number of the problematic vaccine has been discontinued, and parents are urged to rest assured.
Sanofi Pharmaceutical Factory responded that it had requested the competent authorities in Taiwan to retrieve the vaccine and would submit it to the test as soon as possible. It will also form a special task force to speed up the processing progress and find out the reasons.
However, it is not the first time that the influenza vaccine of Sanofi Pharmaceuticals has had problems. In 2018, less than two weeks after Taiwan's public-fund influenza vaccine was launched, one public-fund vaccine was found to have discolored. Later, it was found that there were white suspended substances and black particles in the vaccine.
Sanofi Pharmaceutical Factory said that the causes of the previous three defective influenza vaccine incidents vary. The vaccine discoloration incident was caused by the carbonization of glue plugs. The white suspended substance is the packaging material. The black particles are also related to the glue plug, but they are not caused by the carbonization. It may be that the particles on the glue plug have not been completely cleaned. The vaccines found at present must be retested before the cause can be found, but the judgment is not a systematic problem.
